Paragraf, a Somersham, Cambridgeshire, UK-based technology company delivering commercial quality, graphene-based electronic devices, raised $60M in Series B funding.
The round was led by New Science Ventures, with participation from Parkwalk, Amadeus Capital Partners, IQ Capital and Molten Ventures, British Patient Capital, and In-Q-Tel.
The company intends to use the funds to scale the business increasing its sales and technical prowess in the UK, US, EU and Asia, boosting its R&D capabilities to advance its technology and product development capacity, and expanding its manufacturing infrastructure.
Led by CEO Dr Simon Thomas, Paragraf has developed graphene electronic devices perfecting a process for producing single-atom thick, two-dimensional materials, including graphene, directly onto crystalline substrates, such as: silicon, silicon-carbide, sapphire and gallium-nitride. The contamination-free technology is scalable, and compatible with existing electronic device manufacturing production processes.
The company’s current products, the graphene Hall Effect Sensor range, are already being used in a wide range of applications across the aerospace, semiconductor, healthcare, automotive, scientific research, industrial and quantum computing spaces. The next breakthrough product, a graphene-based biosensor that’s targeted at transforming clinical point of care in the medical industry, is in the pipeline.
Paragraf has already collaborated with world-renowned organisations such as CERN, the National Physical Laboratory, and Rolls Royce.
FinSMEs
01/03/2022